Malaria
Conditions
Interventions
Moderate dose Artesunate intranasal doses
Low dose intranasal artesunate
High dose intranasal artesunate
Sponsors
University of sciences techniques and technologies of Bamako
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Potential subjects are required to meet all of the following criteria for enrollment into the study: Healthy adults between the ages 18-25 (inclusive); Able and willing to provide written, informed consent; Able and willing to comply with all research requirements, in the opinion of the Investigator; Axillary temperature 140,000/mm
Exclusion criteria
Exclusion criteria: Subjects meeting any of the following criteria are not eligible for inclusion in this study. 1. Ages 25; 2. Pregnant or lactating female 3. Not able or not willing to provide written, informed consent; 4. Signs and symptoms of severe or non-severe malaria according to WHO 2015 criteria 5. Active infections including tuberculosis 6. Axillary temperature = 37.5°C 7. Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection 8. Severe malnutrition (body mass index (BMI) less than 70% of median normalized WHO reference weight) 7. Severe vomiting (defined as more than 3 times in the 24 hours prior to inclusion in the study) or severe diarrhea (defined as more than 3 watery stools in the 24 hours prior to inclusion in the study) 8. Anemia (Hemoglobin level < 11.7 g/dL) 9. History of malignancy of any organ system (other than localized basal cell carcinoma of the skin or in situ cervical cancer), treated or untreated, within the past 5 years, regardless of whether there is evidence of local recurrence or metastases 10. Known chronic underlying disease such as sickle cell disease, and severe cardiac, renal, or hepatic impairment 11. Known active or uncontrolled ear, nose and throat (ENT) disease 12. Inability to tolerate oral medication (in tablet and/or liquid form) 13. Patients with prior antimalarial therapy within minimum of 4 weeks 14. Use of other investigational drugs within 5 half-lives of enrollment, or within 30 days or until the expected pharmacodynamic effect has returned to baseline, whichever is longer 15. History or family history of long QT syndrome or sudden cardiac death, or any other clinical condition known to prolong the QTc interval, such as history of symptomatic cardiac arrhythmias, clinically relevant bradycardia or severe heart disease 16. History of hypersensitivity to artesunate and dihydroartemisinin, or its excipients or to drugs of similar chemical classes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the pharmacokinetic parameters of intranasal administration of artesunate powder. Endpoints: artesunate and dihydroartemisinin Cmax, Tmax and AUC0-24h | — |
Secondary
| Measure | Time frame |
|---|---|
| To evaluate safety and tolerability of intranasal administration of artesunate powder. Endpoints: AE/SAE incidence and severity, hematology tests, electrocardiogram abnormalities | — |
Countries
Mali
Contacts
Public ContactAnne Lise Bienvenu
Hospital practcian
Outcome results
None listed